Pharmacokinetics in Sprague-Dawley rats and Beagle dogs and in vitro metabolism of ZJM-289, a novel nitric dioxide donor

Reference

• Bahar FG, Ohura K, Ogihara T, Imai T. (2012). Species difference of esterase expression and hydrolase activity in plasma. J Pharm Sci 101:3979–88
   PubMed Web of Science ®Google Scholar
• Berry LM, Wollenberg L, Zhao Z. (2009). Esterase activities in the blood, liver and intestine of several preclinical species and humans. Drug Metab Lett 3:70–7
   PubMedGoogle Scholar
• Brandon EF, Raap CD, Meijerman I, et al. (2003). An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicol Appl Pharmacol 189:233–46
   PubMed Web of Science ®Google Scholar
• Burkhardt JE, Biehl ML, Kowsz KP, et al. (1998). Effects of cholestyramine and diet on small intestinal histomorphometry in rats. Toxicol Pathol 26:271–5
   PubMedGoogle Scholar
• Clarke SE, Jeffrey P. (2001). Utility of metabolic stability screening: comparison of in vitro and in vivo clearance. Xenobiotica 31:591–8
   PubMed Web of Science ®Google Scholar
• Cubitt HE, Houston JB, Galetin A. (2011). Prediction of human drug clearance by multiple metabolic pathways: integration of hepatic and intestinal microsomal and cytosolic data. Drug Metab Dispos 39:864–73
   PubMed Web of Science ®Google Scholar
• Fujitaki JM, Cable EE, Ito BR, et al. (2008). Preclinical pharmacokinetics of a HepDirect prodrug of a novel phosphonate-containing thyroid hormone receptor agonist. Drug Metab Dispos 36:2393–403
   PubMed Web of Science ®Google Scholar
• Houston JB. (1994). Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469–79
   PubMed Web of Science ®Google Scholar
• Iwatsubo T, Hirota N, Ooie T, et al. (1997). Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73:147–71
   PubMed Web of Science ®Google Scholar
• Li N, Wang X, Li T, et al. (2011a). Identification of circulatory and excretory metabolites of a novel nitric oxide donor ZJM-289 in rat plasma, bile, urine and faeces by liquid chromatography-tandem mass spectrometry. Xenobiotica 41:805–17
   PubMed Web of Science ®Google Scholar
• Li Y, Wang X, Fu R, et al. (2011b). Synthesis and evaluation of nitric oxide-releasing derivatives of 3-N-butylphthalide as anti-platelet agents. Bioorg Med Chem Lett 21:4210–14
   PubMed Web of Science ®Google Scholar
• Liederer BM, Borchardt RT. (2006). Enzymes involved in the bioconversion of ester-based prodrugs. J Pharm Sci 95:1177–95
   PubMed Web of Science ®Google Scholar
• Niu Z, Chen F, Sun J, et al. (2008). High-performance liquid chromatography for the determination of 3-N-butylphthalide in rat plasma by tandem quadrupole mass spectrometry: application to a pharmacokinetic study. J Chromatograph B 870:135–9
   PubMedGoogle Scholar
• Obach RS, Baxter JG, Liston TE, et al. (1997). The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46–58
   PubMed Web of Science ®Google Scholar
• Paine MF, Khalighi M, Fisher JM, et al. (1997). Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283:1552–62
   PubMed Web of Science ®Google Scholar
• Peng Y, Sun J, Hon S, et al. (2010). L-3-N-butylphthalide improves cognitive impairment and reduces amyloid-beta in a transgenic model of Alzheimer's disease. J Neurosci 30:8180–9
   PubMed Web of Science ®Google Scholar
• Peng Y, Zeng X, Feng Y, Wang X. (2004). Antiplatelet and antithrombotic activity of L-3-N-butylphthalide in rats. J Cardiovasc Pharmacol 43:876–81
   PubMed Web of Science ®Google Scholar
• Qiu Z, Li N, Wang X, et al. (2013). Pharmacokinetics of vicagrel, a promising analog of clopidogrel, in rats and Beagle dogs. J Pharm Sci 102:741--9
   PubMed Web of Science ®Google Scholar
• Wang NN, Le LY, Jiang XH, et al. (2012a). Determination of 3-n-butylphthalide in rat plasma by RP-HPLC and its pharmacokinetics. Chin J New Drugs Clin Rem 31:743–7
   Google Scholar
• Wang X, Zhao Q, Li T, et al. (2012b). Studies on the enantiomers of ZJM-289: synthesis and biological evaluation of antiplatelet, antithrombotic and neuroprotective activities. Org Biomol Chem 10:9030–40
   PubMedGoogle Scholar
• Xu HL, Feng YP. (2000). Inhibitory effects of chiral 3-N-butylphthalide on inflammation following focal ischemic brain injury in rats. Acta Pharmacol Sin 21:433–8
   PubMed Web of Science ®Google Scholar
• Xu HL, Feng YP. (2001). Effects of 3-N-butylphthalide on thrombosis formation and platelet function in rats. Yao Xue Xue Bao 36:329–33
   PubMedGoogle Scholar
• Yang B, Lu Y, Zheng J, et al. (2011). Pharmacokinetics of the prodrug thiamphenicol glycinate and its active parent compound thiamphenicol in Beagle dogs following intravenous administration. Xenobiotica 41:226–31
   PubMed Web of Science ®Google Scholar
• Yang J, Jamei M, Yeo KR, et al. (2007). Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 8:676–84
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang L, Li J, Wang XL. (2006). 2-(1-Hydroxypentyl)-benzoate increases cerebral blood flow and reduces infarct volume in rats model of transient focal cerebral ischemia. J Pharmacol Exp Ther 317:973–9
   PubMed Web of Science ®Google Scholar
• Zhao Q, Zhang C, Wang X, et al. (2012). (S)-ZJM-289, a nitric oxide-releasing derivative of 3-n-butylphthalide, protects against ischemic neuronal injury by attenuating mitochondrial dysfunction and associated cell death. Neurochem Int 60:134–44
   PubMed Web of Science ®Google Scholar
• Zhuang P, Ji H, Zhang YH, et al. (2010). ZJM-289, a novel nitric oxide donor, alleviates the cerebral ischaemic-reperfusion injury in rats. Clin Exp Pharmacol Physiol 37:e121–7
   PubMedGoogle Scholar